Gilead Sciences Inc

Type: Company
Name: Gilead Sciences Inc
First reported 3 hours ago - Updated 3 hours ago - 1 reports

Drug sales bolster J&J's bottom line [The Philadelphia Inquirer :: ]

April 20--The old wives' tale that you will catch a cold if you don't bundle up was formally laid to rest last week when Johnson & JohnsonThere it was in the words of Dominic Caruso, J&J's chief financial officer: "Despite the severe weather conditions, ... [Published BusinessWeek - 3 hours ago]
First reported 3 hours ago - Updated 3 hours ago - 1 reports

Earnings Expectations For The Week Of April 21: Apple, Facebook, GM And More

The earnings crunch is underway.Highlights this week include scheduled quarterly reports from Amazon.com, Apple, Facebook, Netflix and Starbucks, which are all expected to post earnings growth, as well as from Ford, McDonald's and Microsoft, for which ... [Published Benzinga.com - 3 hours ago]
First reported 5 hours ago - Updated 5 hours ago - 1 reports

NHS England agrees funding for Gilead’s hepatitis C drug Sovaldi

NHS England has approved an £18.7 million ($31.3 million) investment in a new drug for the treatment of hepatitis C, US biotech firm Gilead Sciences’ (Nasdaq: GILD) Sovaldi (sofosbuvir).Around 500 patients with acute liver failure, and/or awaiting liver ... [Published Pharma Letter - 5 hours ago]
First reported 11 hours ago - Updated 11 hours ago - 1 reports

Household wealth up $25 trillion, but spending lags

Number of the dayMore than $25 trillionThe amount American household wealth has increased since early 2009. The jump came amid rising equity and home prices, but the pass-through to consumer spending is lagging the $1 trillion boost that would have been ... [Published San Francisco Chronicle - 11 hours ago]
First reported 12 hours ago - Updated 12 hours ago - 1 reports

Top Healthcare and Biotech Focused Hedge Funds Surge; Oversee $70 Billion in Equity Assets

The most recent Top 50 Healthcare, Pharmaceutical and Biotechnology Focused Hedge Fund list has been released, revealing that the top hedge funds now manage $70 billion in U.S. equity assets. Larry Robbins’ Glenview Capital Management has retained the ... [Published Hedge Tracker - 12 hours ago]
First reported Apr 19 2014 - Updated Apr 19 2014 - 1 reports

IL government orders taxpayers to provide inmates with $84,000 prescriptions for Hepatitis C

Sovaldi will wreck American health care with its $84k price tag. Even though the same prescription is sold in Egypt for $900.About 3.2 million Americans have chronic infections from Hepatitis C. Over half caught it from sharing needles. Much of the rest ... [Published COFCC - Apr 19 2014]
First reported Apr 19 2014 - Updated Apr 19 2014 - 1 reports

Product Manager/Sr. Product Manager, HBV Promotions

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. With each new discovery and investigational drug candidate, we seek to improve the care ... [Published PharmaDiversity - Apr 19 2014]
First reported Apr 18 2014 - Updated Apr 18 2014 - 1 reports

3 Reasons the Market Is Down on Gilead Sciences

After a solid two-year run, Gilead Sciences   ( NASDAQ: GILD     ) has fallen from investors graces, down for the year. The biotech has become increasingly reliant on its hepatitis C drug Sovaldi, with competition from  AbbVie ( NYSE: ABBV     ) and  ... [Published Motley Fool Discussion Boards - Apr 18 2014]
First reported Apr 18 2014 - Updated Apr 18 2014 - 1 reports

Why People Love Working For Big Pharmas Like Biogen Idec, Inc. (California), Celgene, And Gilead Sciences, Inc.

Companies like Celgene, Biogen Idec, and Gilead Sciences all took top spots on our list of the Best Employers in America. Clearly there are a lot of people who love working in pharma and biotech — but why? Biotech companies have plenty of perks, sometimes ... [Published BioSpace - Apr 18 2014]
First reported Apr 18 2014 - Updated Apr 18 2014 - 5 reports

UK Authortity To Spend ??18.7 Million To Make Gilead Sciences, Inc.'s Sovaldi Available To Most Grave Patients

NHS England is to spend £18.7 million to make new Hepatitis C treatment Sovaldi available to patients with the most advanced disease. Around 500 patients who have acute liver failure, and/or awaiting liver transplantation, are set to benefit from the ... [Published BioSpace - Apr 18 2014]
First reported Apr 18 2014 - Updated Apr 18 2014 - 1 reports

Pipefitter (Maintenance Engineering Tech II)

Gilead Sciences, ULC located in Edmonton, Alberta is seeking a knowledgeable and experienced Journeyman Pipefitter to assume full-time responsibilities in Gilead's Maintenance and Engineering department immediately.Gilead Sciences, Inc. is a research-based ... [Published PharmaDiversity - Apr 18 2014]
First reported Apr 18 2014 - Updated Apr 18 2014 - 1 reports

Gilead Announces U.S. FDA Priority Review Designation for Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Chronic Hepatitis C Genotype 1 Infection

(NewsRx) -- By a News Reporter-Staff News Editor at Hepatitis Weekly -- Gilead Sciences, Inc. (Nasdaq: GILD) announced that the U.S. Food and Drug Administration (FDA) has granted priority review to the company's New Drug Application (NDA) for a once-daily ... [Published NewsRX - Apr 18 2014]

Quotes

"Yes, it's done better than we expected," Caruso said in the post-earnings conference call when asked about Olysio. "It's primarily due to the fact that the Liver Society issued guidelines in January recommending the use of Olysio, along with the product from Gilead, Sovaldi. That has been adopted by the community -- by the medical community -- as a standard of care."
...huge mistake in companies, building a strategy on quarterly earnings alone," said Brian Belski, chief investment strategist at BMO Capital Markets. "The recovery is more of a marathon than a sprint."
"The underlying concern is that there will not be enough cocoa available to satisfy the appetite of consumers."
Some may never come back. Hickey is dubious about 3-D printers. "All they are making is prototypes and plastic tchotchkes. It's years down the road, it's a concept."

More Content

All (1980) | News (1707) | Reports (0) | Blogs (231) | Audio/Video (0) | Fact Sheets (7) | Press Releases (28)
sort by: Date | Relevance
Drug sales bolster J&J's bottom line [The Phila... [Published BusinessWeek - 3 hours ago]
Earnings Expectations For The Week Of April 21:... [Published Benzinga.com - 3 hours ago]
NHS England agrees funding for Gilead’s hepatit... [Published Pharma Letter - 5 hours ago]
MARKET SNAPSHOT: Long View On Stocks Is Best Du... [Published 4 Traders - 9 hours ago]
Household wealth up $25 trillion, but spending ... [Published San Francisco Chronicle - 11 hours ago]
Top Healthcare and Biotech Focused Hedge Funds ... [Published Hedge Tracker - 12 hours ago]
Once high-flying stocks lose momentum, it's har... [Published San Francisco Chronicle - 20 hours ago]
Insurers Fret Hepatitis C Pill Costs Along With... [Published Forbes.com - Apr 19 2014]
Obamacare Expands: What You Need to Know [Published Motley Fool - Apr 19 2014]
Why the Worst of the Growth-Stock Smackdown May... [Published Money And Markets - Apr 19 2014]
IL government orders taxpayers to provide inmat... [Published COFCC - Apr 19 2014]
Product Manager/Sr. Product Manager, HBV Promot... [Published PharmaDiversity - Apr 19 2014]
California improves access to HIV prevention pill [Published Project Inform - Apr 19 2014]
3 Reasons the Market Is Down on Gilead Sciences [Published Motley Fool Discussion Boards - Apr 18 2014]
Royalty Financing Partnering Terms and Agreemen... [Published SBWire - Apr 18 2014]
Has Momentum Investing Lost its Mojo? [Published Nasdaq - Apr 18 2014]
"Option and Evaluation Partnering Terms and Agr... [Published SBWire - Apr 18 2014]
Blockbuster Drug Boycott? What ESI's Sovaldi Th... [Published Medical Marketing And Media - Apr 18 2014]
UPDATE 1-EXCLUSIVE-Biogen prices hemophilia dru... [Published CNBC - Apr 18 2014]
Thomson Reuters Names Drugs to Watch in 2014 [Published PharmTech.com - Apr 18 2014]
New Hepatitis C drug, a big boon for domestic p... [Published The Hindu - Apr 18 2014]
EXCLUSIVE : Biogen prices hemophilia drug on pa... [Published 4 Traders - Apr 18 2014]
Why People Love Working For Big Pharmas Like Bi... [Published BioSpace - Apr 18 2014]
Asset Purchase Terms and Agreements in Pharma, ... [Published SBWire - Apr 18 2014]
Recent Study: Personalized Medicine Partnering ... [Published Digital Journal - Apr 18 2014]
UK Authortity To Spend ??18.7 Million To Make G... [Published BioSpace - Apr 18 2014]
Cohen’s Point72 Asset Management buys a stake i... [Published Yahoo! Finance - Apr 18 2014]
NHS England approves $13.5M in funding for hepa... [Published Center Watch - Apr 18 2014]
These Stocks Will Prosper Regardless of Obamaca... [Published Money Morning - Apr 18 2014]
NHS England approves $13.5M in funding for hepa... [Published BioPortfolio - Apr 18 2014]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Thomas Reuters Projects Next Blockbusters [Published The Big Red Biotech Blog - Apr 17 2014]
Thomas Reuters analysts just projected the next round of drugs that they feel should be watched a the new blockbusters on the block in the coming year. The list has some sure things and perhaps some surprises. In order of liklihood and sales: Gilead's ...
UnitedHealth: New hepatitis C drug costs far mo... [Published Yahoo! Health News - Apr 17 2014]
UnitedHealth Group Inc, the largest U.S. health insurer, said it spent more than $100 million to cover a pricey new hepatitis C drug from Gilead Sciences Inc in its first three months on the market, an amount that was "multiple" times wh... ...
Generic Drugmakers Fight Teva’s Bid to Stall Co... [Published Wall St. Cheat Sheet - Apr 17 2014]
Generic drugmakers asked the U.S. Supreme Court to allow them to introduce generic versions of   Teva Pharmaceutical Industries Ltd.’s ( NYSE:TEVA ) Copaxone multiple-sclerosis drug onto the market next month, according to Reuters and Bloomberg ...
Gilead Sciences (GILD) Trading Near $67.62 Supp... [Published MarketIntelligenceCenter.com - Apr 17 2014]
After closing Wednesday at $69.28, Gilead Sciences Inc (GILD) presents an attractive opportunity to get a 6.66% return in just 65 days, which is an annualized return of 37.39% (for comparison purposes only). To enter this trade, sell one Jun. '14 $70.00 ...
Is Merck a Hot Stock? [Published Wall St. Cheat Sheet - Apr 16 2014]
With shares of Merck ( NYSE:MRK ) trading around $56, is MRK an OUTPERFORM, WAIT AND SEE, or STAY AWAY? Let’s analyze the stock with the relevant sections of our CHEAT SHEET investing framework : T = Trends for a Stock’s Movement Merck is a global ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
Financial Release Dates -- Research on Gilead S... [Published Financial Services - Apr 14 2014]
Priority Reviews, Preliminary Earnings Releases... [Published Financial Services - Apr 11 2014]
Clinical Trial Results Presentation and Publica... [Published Financial Services - Apr 09 2014]
Senior Notes Conversions, FDA Drug Approvals, A... [Published Financial Services - Apr 03 2014]
Pending Applications, Closed Public Offering, J... [Published Financial Services - Apr 01 2014]
1 2 3 4 5 6
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.